Karius
PrivateLast Round
Series C
May 2, 2024
Est. Valuation
$700M
Total Funding Raised
$350.27M
Company Overview
Karius is a biotechnology company that provides genomic testing for infectious diseases by analyzing microbial DNA from blood samples to assist physicians in making rapid treatment decisions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical AI, Precision Medicine, Medical Devices, Healthcare Analytics
Business Model
B2B
Customer Profile
Usage-Based SaaS, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Karius Comparables
Compare Karius with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Delve Bio | 76% | |
| Illumina, Inc. | 76% | |
| Vision Medicals | 75% |
Karius Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | May 2, 2024 | ||||
| Series B | Feb 24, 2020 | ||||
| Debt | Nov 29, 2018 | ||||
| Series A | Aug 7, 2017 | ||||
| Seed | Oct 20, 2014 | ||||
Seed | Sep 1, 2014 |
Karius Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SoftBank Investment Advisers | Series C, Series B |
| Waycross Ventures | Series C |
| Khosla Ventures | Series B, Series A, Series C |
| S28 Capital | Seed, Series A |
| Innovation Endeavors | Series C, Seed, Series A |
| SoftBank Group | Series C, Series B |
| 5AM Ventures | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2025
Karius Focus BAL test identifies 500 pathogens from BAL fluid.
- Oct 1, 2025
Karius Spectrum identifies over 1,000 pathogens from a single blood sample.
Recent news
Latest coverage and updates
- hiresSep 8, 2026
Karius, Inc. hired Stas Zvinyatskovsky as Vice President of Engineering on Sep 8th '26.
Karius Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Karius's valuation, stock price, and market status.
Is Karius a public or private company?
Karius is a private company.
What is the current stock price of Karius?
Karius is a private company with no public stock price. No recent secondary market data is available.
How much is Karius worth (valuation)?
Valuation information for Karius is not publicly available.
Can I buy Karius stock?
Karius shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Karius's last funding round?
Karius's most recent funding round was Series C on May 2, 2024.
Who are the main investors in Karius?
Key investors in Karius include SoftBank Investment Advisers, Khosla Ventures, S28 Capital, SoftBank Group, 5AM Ventures.
Will Karius IPO soon?
No public IPO plans have been announced for Karius.
How can I track Karius secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Karius's secondary market activity and sign up for updates.